Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly

Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly

Published 1 day, 1 hour ago
Description
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us